Eldecalcitol: A review of its use in the treatment of osteoporosis

Drugs

Volumn 71, Issue 13, 2011, Pages 1755-1770

  Sanford, Mark ^a   McCormack, Paul L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Eldecalcitol; Osteoporosis

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; CALCIUM; EDIROL; ELDECALCITOL; OSTEOCALCIN; PARATHYROID HORMONE; PLACEBO; SIMVASTATIN; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATASE BLOOD LEVEL; BIOMECHANICS; BONE STRUCTURE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CALCIUM URINE LEVEL; CONJUNCTIVITIS; CYSTITIS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; EMBASE; FEMUR; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERCALCEMIA; KIDNEY DISEASE; LIVER DISEASE; MEDLINE; OSSIFICATION; OSTEOPOROSIS; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SIDE EFFECT; STOMACH PAIN; UROLITHIASIS; VERTEBRA FRACTURE;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; HUMANS; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITAMIN D;

EID: 80052633753     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11206790-000000000-00000     Document Type: Review

References (38)

1. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann InternMed 2008 Feb 5; 148 (3): 197-213 (Pubitemid 351665507)
2. World Health Organization. Prevention and management of osteoporosis [online]. Available from URL: http://whqlibdoc. who.int/trs/who-trs-921.pdf [Accessed 2010 Sep 28]
3. National Osteoporosis Guideline Group. Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK [online]. Available from URL: http://www. shef.ac.uk/NOGG/NOGG- PocketGuide-for-Healthcare-Professionals.pdf [Accessed 2010 Nov 19]
4. Kanis JA, McCloskey EV, Johansson H, et al. Approaches to the targeting of treatment for osteoporosis. Nat Rev Rheumatol 2009 Aug; 5 (8): 425-31
5. Fujiwara S. Epidemiology of osteoporosis in Japan. J Bone Mineral Metab 2005; 23 Suppl. 1: 81-3
6. International Osteoporosis Foundation. About osteoporosis [online]. Available from URL: http://www.iofbonehealth. org/health-professionals/about- osteoporosis/epidemiology.html [Accessed 2010 Dec 13]
7. World Health Organization. WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level: summary meeting report May 2004 [online]. Available from URL: http://who.int/chp/topics/Osteoporosis.pdf [Accessed 2010 Sep 28]
8. Gruntmanis U. Male osteoporosis: deadly, but ignored. Am J Med Sci 2007 Feb; 333 (2): 85-92
9. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002 Nov 2; 359 (9321): 1929-36 (Pubitemid 34615775)
10. Orimo H,Hayashi Y, Fukunaga M, et al. Diagnostic criteria for primary osteoporosis: year 2000 revision. J BoneMiner Metab 2001; 19 (6): 331-7 (Pubitemid 33041725)
11. Bikle DD. What is new in vitamin D: 2006-2007. Curr Opin Rheumatol 2007 Jul; 19 (4): 383-8 (Pubitemid 46884196)
12. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006 Mar; 81 (3): 353-73 (Pubitemid 43334631)
13. Office of Dietary Supplements NIH. Dietary supplement fact sheet: vitamin D [online]. Available from URL: http:ods.od.nih.gov/factsheets/vitamind/ [Accessed 2010 Nov 6]
14. Saag KG, Geusens P. Progress in osteoporosis and fracture prevention: focus on postmenopausal women. Arthritis Res Ther 2009; 11 (5): E251
15. Nishii Y. Rationale for active vitamin D and analogs in the treatment of osteoporosis. J Cell Biochem 2003 Feb 1; 88 (2): 381-6 (Pubitemid 36119912)
16. Jones G. Vitamin D analogs. Endocrinol Metab Clin North Am 2010; 39 (2): 447-72
17. Edirol(eldecalcitol tablets): Japanese prescribing information. Tokyo: Chugai, 2011
18. Kubodera N, Tsuji N, Uchiyama Y, et al. A new active vitamin D analog, ED-71, causes increase in bonemass with preferential effects on bone in osteoporotic patients. J Cell Biochem 2003 Feb 1; 88 (2): 286-9 (Pubitemid 36119900)
19. Matsumoto T, Takano T, Yamakido S, et al. Comparison of the effects of eldecalcitol and alfacalcidol on bone and calcium metabolism. J Steroid Biochem Mol Biol 2010 Jul; 121 (1-2): 261-4
20. Hatakeyama S, Nagashima S, Imai N, et al. Synthesis and biological evaluation of a 3-positon epimer of 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy) vitamin D3 (ED-71). J Steroid Biochem Mol Biol 2007 Mar; 103 (3-5): 222-6 (Pubitemid 46401295)
21. Uchiyama Y, Higuchi Y, Takeda S, et al. ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone 2002 Apr; 30 (4): 582-8 (Pubitemid 34270495)
22. Matsumoto T, Miki T, Hagino H, et al. A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, doubleblind, placebo-controlled clinical trial. J Clin Endocrinol Metab 2005 Sep; 90 (9): 5031-6 (Pubitemid 41262250)
23. Matsumoto T, Ito M, Hayashi Y, et al. A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures: a randomized, active comparator, double-blind study. Bone. Epub 2011 Jul 19
24. Ito M, Nakamura T, Fukunaga M, et al. Effect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CT. Bone 2011 Sep; 49 (3): 328-34
25. Abe M, Tsuji N, Takahashi F, et al. Overview of the clinical pharmacokinetics of eldecalcitol, a new active vitamin D3 derivative. Jpn Pharmacol Ther 2011; 39 (3): 261-74
26. Miyata K, Abe M, Terao K, et al. Pharmacokinetics of eldecalcitol in primary osteoporosis patients: randomized, double-blind, multicentre, long-term phase III clinical study. Jpn Pharmacol Ther 2011; 39 (3): 299-307
27. Miyata K, Ohba Y, Abe M, et al. Effects of eldecalcitol on the pharmacokinetics of the CYP3A4 substrate, simvastatin: double blind, randomized, placebo-controlled, parallel group comparative study in healthy male volunteers. Jpn Pharmacol Ther 2011; 39 (3): 275-85
28. Ikeda Y, Kumagai Y, Arinaga T, et al. Open-label, multicentre, single dose study of eldecalcitol pharmacokinetics in patients with impaired liver function. Jpn Pharmacol Ther 2011; 39 (3): 287-97
29. Matsumoto T, Kubodera N. ED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects. J Steroid Biochem Mol Biol 2007 Mar; 103 (3-5): 584-6 (Pubitemid 46401355)
30. Cheung AM, Detsky AS. Osteoporosis and fractures: missing the bridge? JAMA 2008 Mar 26; 299 (12): 1468-70 (Pubitemid 351468446)
31. Qaseem A, Snow V, Shekelle P. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008 Sep 16; 149 (6): 404-15
32. Committee of Japanese Guidelines for the Prevention and Treatment of Osteoporosis. The Japanese guidelines for the prevention and treatment of osteoporosis (2006 edition-abridged). Osteoporosis Japan 2007; 15 (2): 221-5
33. Papadimitropoulos E, Wells G, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. VIII: meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Endocrine Rev 2002 Aug; 23 (4): 560-9 (Pubitemid 34925650)
34. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a metaanalysis of randomized controlled trials. JAMA 2005 May 11; 293 (18): 2257-64 (Pubitemid 40629192)
35. Richy F, Schacht E, Bruyere O, et al. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int 2005; 76 (3): 176-86 (Pubitemid 41557146)
36. Avenell A, Gillespie WJ, Gillespie LD, et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2009; (2): CD000227
37. Ringe JD. Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat. Rheumatol Int 2010 May; 30 (7): 863-9
38. Sellmeyer DE. Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA 2010 Oct 6; 304 (13): 1480-4